I agree that's what Pazdur believes. There is a world of difference between COngressional requirement of doing the confirmatory and requiring it be substantially complete before accelerated approval is granted. Pazdur's way increases costs and slows development, which is the opposite of leg intent.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr